NASDAQ:GLUE Monte Rosa Therapeutics Q1 2025 Earnings Report $4.43 +0.02 (+0.45%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$4.40 -0.03 (-0.65%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Monte Rosa Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.24Beat/MissN/AOne Year Ago EPSN/AMonte Rosa Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$13.57 millionBeat/MissN/AYoY Revenue GrowthN/AMonte Rosa Therapeutics Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Remove Ads Monte Rosa Therapeutics Earnings HeadlinesMonte Rosa Therapeutics: Exercise Extreme CautionMarch 25, 2025 | seekingalpha.comMonte Rosa Therapeutics price target raised to $17 from $15 at WedbushMarch 23, 2025 | markets.businessinsider.comWhy "Made in America" could cost millions their jobPresident Trump promised tariffs will bring jobs home... that factories will soon be full again... and that American workers will thrive. But buried in the fine print is a dark truth... Those factories are filled with a much different kind of worker.April 16, 2025 | Stansberry Research (Ad)Monte Rosa Therapeutics price target lowered to $10 from $11 at Wells FargoMarch 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comPiper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)March 22, 2025 | markets.businessinsider.comSee More Monte Rosa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email. Email Address About Monte Rosa TherapeuticsMonte Rosa Therapeutics (NASDAQ:GLUE), a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.View Monte Rosa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Upcoming Earnings Netflix (4/17/2025)American Express (4/17/2025)Blackstone (4/17/2025)Infosys (4/17/2025)Marsh & McLennan Companies (4/17/2025)Charles Schwab (4/17/2025)Taiwan Semiconductor Manufacturing (4/17/2025)UnitedHealth Group (4/17/2025)HDFC Bank (4/18/2025)Progressive (4/18/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
